Yale Medical Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th Floor Multispecialty Care Center
New Haven, CT 06511
- Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511
Stuart Seropian, MD
Medical Oncology, Hematology & Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Biography
Stuart Seropian, MD, is a medical oncologist who specializes in treating patients with blood cancers, including acute and chronic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. Dr. Seropian also sees patients with non-cancerous bone marrow disorders, including aplastic anemia. He is director of the adult Stem Cell Transplant program and co-director of the CAR T-cell Therapy Program for adults.
In medical school, Dr. Seropian enjoyed studying the biology of cancer and wanted to provide long-term patient care, which led to his pursuing medical oncology. “I have patients who see me as their primary care physician—as the doctor most responsible for their long-term care,” Dr. Seropian says. “Patients will say they’ve experienced a physician who had one foot out the door before all questions were answered. But the relationship with the patient is vital for cancer treatment.”
During his career, Dr. Seropian has witnessed treatment options for patients with blood cancers improve by leaps and bounds, from chemotherapy to the personalized CAR T-cell and stem cell transplantation therapies.
“The general view among the public is that cancer is terminal,” Dr. Seropian says. “People are always surprised to hear that cure rates [for certain cancers] range from 30 to 65 percent.”
He points out that a transplant physician is one of many providers of care in a large cast, which includes other physician subspecialists, nurse practitioners, nurses, coordinators, laboratory physicians and technicians. “Patients who come here are cared for by a family of people,” he says.
Dr. Seropian is an associate professor of medicine (hematology) at Yale School of Medicine.
Titles
- Professor of Internal Medicine (Hematology)
- Acting Director, Stem Cell Transplantation
- Chairman, Car-T Cell Joint Steering Committee
- Director, Unrelated Donor Transplant Program, Stem Cell Transplantation
- Co-Director, Immune Effector Cell Therapy
- Co-Director, Adult CAR T-Cell Therapy Program
Education & Training
- ResidentYale-New Haven Hospital (1994)
- InternYale-New Haven Hospital (1992)
- MDGeorge Washington University (1991)
- BSTufts University (1984)
Additional Information
Honors & Recognitions
- Yale Cancer Center Award for Clinical Excellence: Yale Cancer Center (2016)
- David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology: Yale Cancer Center (2014)
- Alpha Omega Alpha Medical Honor Society: AOA (1991)
- MD with Distinction, George Washington University School of Medicine: George Washington University School of Medicine (1991)
- Horowitz Award, NBME Part I: George Washington University School of Medicine (1989)
Board Certifications
- AB of Internal Medicine, Medical Oncology (1997, recertified: 2018)
Professional Service
- Hodgkin’s Lymphoma Guidelines Panel, National Comprehensive Cancer Center Network (2016 - Present): Committee Member
- EMR User Group, Center for International Blood and Marrow Transplantation Research (CIBMTR) (2014 - Present): Member
- Bone Marrow Transplantation (2014 - Present): Ad Hoc Reviewer of journal submissions
- Transfusion (2014 - Present): Reviewer
- Search Committee, Chair of Pulmonary Section, Department of Medicine (2008 - 2010): Member
- Education Review Committee (2007 - 2008): Member
- Internship Selection Committee (2006 - 2007): Member
- The Bone Marrow Foundation (2001 - Present): Regular participant in public access patient/family online advice query activities.
- Protocol Review Committee (1999 - 2017): review all clinical research protocols submitted for scientific review in the Cancer Center prior to IRB submission
Publications
- Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Mirza A, Hamouche R, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s383-s384. DOI: 10.1016/s2666-6367(23)00581-x.
- Hamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s387-s388. DOI: 10.1016/s2666-6367(23)00585-7.
- Di M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen Transplantation And Cellular Therapy 2023, 29: s392. DOI: 10.1016/s2666-6367(23)00591-2.
- Di M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
- Browning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
- Liu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
- Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.
- Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
- Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Chen G, Al-Kadhimi Z, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. 40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies Transplantation And Cellular Therapy 2022, 28: s35-s36. DOI: 10.1016/s2666-6367(22)00201-9.
- Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease Journal Of Clinical Oncology 2022, 40: 1174-1185. PMID: 35007144, PMCID: PMC8987226, DOI: 10.1200/jco.21.01755.
- Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Al-Kadhimi Z, Chen G, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies Blood 2021, 138: 1791-1791. DOI: 10.1182/blood-2021-148497.
- Gowda L, Seropian S. Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul? JAMA Oncology 2021, 7: 1611-1613. PMID: 34499090, DOI: 10.1001/jamaoncol.2021.3674.
- Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy Annals Of Hematology 2021, 101: 1145-1147. PMID: 34686913, DOI: 10.1007/s00277-021-04702-w.
- Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.
- Gisriel S, Hung K, Braddock D, Seropian S, Foss F, Robert M, Xu M. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis Human Pathology Case Reports 2021, 24: 200507. DOI: 10.1016/j.ehpc.2021.200507.
- Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.
- Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT) Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.
- Nath R, Gyurkocza B, Choe H, Seropian S, Stiff P, Agura E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 59 Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Transplantation And Cellular Therapy 2021, 27: s56. DOI: 10.1016/s2666-6367(21)00085-3.
- Gerstein R, Schiffer M, Perreault S, Gowda L, Foss F, Isufi I, Seropian S. 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Transplantation And Cellular Therapy 2021, 27: s466-s467. DOI: 10.1016/s2666-6367(21)00606-0.
- Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Agura E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 60 Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered Transplantation And Cellular Therapy 2021, 27: s57-s58. DOI: 10.1016/s2666-6367(21)00086-5.
- Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Journal Of Health-System Pharmacy 2021, 78: zxab072. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Sharma A, Bhatt N, St. Martin A, Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda L, Perales M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study Transplantation And Cellular Therapy 2021, 27: s4-s5. PMCID: PMC7847402, DOI: 10.1016/s2666-6367(21)00031-2.
- Gupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection Transfusion And Apheresis Science 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.
- Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.
- Perreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.
- Browning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. DOI: 10.1182/blood-2020-136478.
- Gupta G, Perreault S, Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection Blood 2020, 136: 41-41. DOI: 10.1182/blood-2020-140171.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-134624.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered Blood 2020, 136: 42-44. DOI: 10.1182/blood-2020-134948.
- Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial Clinical Lymphoma Myeloma & Leukemia 2020, 20: s182. DOI: 10.1016/s2152-2650(20)30716-3.
- Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 755-781. PMID: 32502987, DOI: 10.6004/jnccn.2020.0026.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience* Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Transplantation And Cellular Therapy 2020, 26: s32-s33. DOI: 10.1016/j.bbmt.2019.12.575.
- Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.
- Bewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Shallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center Blood 2019, 134: 5569-5569. DOI: 10.1182/blood-2019-130134.
- Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood 2019, 134: 4055-4055. DOI: 10.1182/blood-2019-128888.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2019, 134: 5642-5642. DOI: 10.1182/blood-2019-122776.
- Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT) Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.
- Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
- Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
- Shallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
- Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN) Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Agura E, Gyurkocza B, Nath R, Litzow M, Tomlinson B, Abhyankar S, Seropian S, Stiff P, Choe H, Kebriaei P, Foran J, Chen G, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2018, 132: 1017-1017. DOI: 10.1182/blood-2018-99-111914.
- Ahmad H, Perreault S, McManus D, Foss F, Isufi I, Seropian S, Topal J. 2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum Infectious Diseases 2018, 5: s746-s746. PMCID: PMC6255683, DOI: 10.1093/ofid/ofy210.2140.
- Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Shimer S, Canavan M, Capasso R, Gore S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute leukemia: Patient-physician differences. Journal Of Clinical Oncology 2018, 36: e22124-e22124. DOI: 10.1200/jco.2018.36.15_suppl.e22124.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 245-254. PMID: 29523663, DOI: 10.6004/jnccn.2018.0013.
- Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies Transplantation And Cellular Therapy 2018, 24: s307. DOI: 10.1016/j.bbmt.2017.12.353.
- Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Musick W, Vuong N, Aitken S, Liao S, McManus D, Cox J, Perez K, Tichy E, Topal J, Seropian S, Danziger L, Garey K. Multi-center Observational Characterization of Cytomegalovirus Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) Recipients Open Forum Infectious Diseases 2017, 4: s715-s715. DOI: 10.1093/ofid/ofx163.1922.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168 Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
- Anderson A, McManus D, Perreault S, Lo YC, Seropian S, Topal JE. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient Medical Mycology Case Reports 2017, 17: 11-13. PMID: 28580237, PMCID: PMC5447657, DOI: 10.1016/j.mmcr.2017.05.004.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 608-638. PMID: 28476741, DOI: 10.6004/jnccn.2017.0064.
- Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.
- Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT) Transplantation And Cellular Therapy 2017, 23: s395-s396. DOI: 10.1016/j.bbmt.2016.12.616.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial Blood 2016, 128: 2139-2139. DOI: 10.1182/blood.v128.22.2139.2139.
- Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis Circulation Cardiovascular Imaging 2016, 9: e004770. PMID: 27682238, DOI: 10.1161/circimaging.116.004770.
- Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.
- Perreault S, Pratt K, Baker J, Medoff E, Foss F, Isufi I, Seropian S, Cooper D. Carmustine Infusion Reactions Are Common and Not Reduced By Lengthening the Time of Administration Transplantation And Cellular Therapy 2016, 22: s130-s131. DOI: 10.1016/j.bbmt.2015.11.462.
- Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.
- Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders Blood 2015, 126: 3058-3058. DOI: 10.1182/blood.v126.23.3058.3058.
- Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- Das R, Sehgal K, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar K, Dhodapkar M. Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets 2015, 1354-1354. DOI: 10.1158/1538-7445.am2015-1354.
- Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 554-86. PMID: 25964641, PMCID: PMC4898052, DOI: 10.6004/jnccn.2015.0075.
- Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.
- Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant Journal For ImmunoTherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.
- Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T‐cell lymphoma British Journal Of Haematology 2014, 167: 141-144. PMID: 24888971, DOI: 10.1111/bjh.12944.
- Disorders of LymphocytesLacy J, Seropian, S, Disorders of Lymphocytes, Andreoli: in Cecil Essentials of Medicine, 9th ed. 2014
- Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience Blood 2013, 122: 5092-5092. DOI: 10.1182/blood.v122.21.5092.5092.
- Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients Blood 2013, 122: 4356-4356. DOI: 10.1182/blood.v122.21.4356.4356.
- Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation Palliative & Supportive Care 2013, 12: 53-61. PMID: 24169207, DOI: 10.1017/s1478951513000552.
- Bleakley M, Heimfeld S, Jones L, Chaney C, Turtle C, Gooley T, Seropian S, Nishihori T, Riddell S, Shlomchik W. Depletion of Naïve T Cells From Peripheral Blood Stem Cell Grafts for GVHD Prevention Transplantation And Cellular Therapy 2013, 19: s318. DOI: 10.1016/j.bbmt.2012.11.477.
- LeukemiaRoberts K, Seropian S, Marks, P, Leukemia, Perez and Brady’s In Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
- Total-Body and HemiBody IrradiationRoberts K, Chen, Z, Seropian S. Total-Body and HemiBody Irradiation, Perez and Brady’s Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
- LymphomaIsufi I, Seropian S, Lymphoma, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
- Plasma Cell DisordersSeropian S, Isufi I, Plasma Cell Disorders, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
- Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.
- Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.
- Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor Journal Of Clinical Apheresis 2012, 27: 235-241. PMID: 22566214, DOI: 10.1002/jca.21232.
- Isufi I, Yao X, Seropian S, Cooper D, Shlomchik W, Deng Y, Barbarotta L, Foss F. Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies Transplantation And Cellular Therapy 2012, 18: s339. DOI: 10.1016/j.bbmt.2011.12.356.
- Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective Evaluation of Acute Graft-Versus-Host Disease Digestive Diseases And Sciences 2011, 57: 720-725. PMID: 22011927, DOI: 10.1007/s10620-011-1938-x.
- King BA, Seropian S, Fox LP. Disseminated fusarium infection with muscle involvement Journal Of The American Academy Of Dermatology 2011, 65: 235-237. PMID: 21679835, DOI: 10.1016/j.jaad.2009.12.034.
- Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.
- Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss F, Cooper D, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood 2010, 116: 1309-1309. DOI: 10.1182/blood.v116.21.1309.1309.
- Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816-2816. DOI: 10.1182/blood.v116.21.2816.2816.
- Lansigan F, Komarovskaya M, Seropian S, Cooper D, Foss F. A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients. Journal Of Clinical Oncology 2010, 28: tps300-tps300. DOI: 10.1200/jco.2010.28.15_suppl.tps300.
- Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis Nature Reviews Clinical Oncology 2010, 7: 415-420. PMID: 20404855, DOI: 10.1038/nrclinonc.2010.40.
- Benjamin I, Tariq S, Beland S, Benjamin I, Bull D, Hamdan M, Li D, Litwin S, Michaels A, Morshedzadeh J, Stehlik J, Whitehead K, Victor R, Vongpatanasin W, Rounds S, Aliotta J, Casserly B, Jankowich M, McCool F, Eagle K, Lau W, Harris R, Andreoli T, Basford A, Cavanaugh K, Dwyer J, Golper T, Krause M, Ikizler T, Lewis J, Luther J, Pirkle J, Portilla D, Safirstein R, Schulman G, Shah S, Zent R, Wolfe M, Blanton W, Bliss C, Farraye F, Huang C, Jacobson B, Lichtenstein D, Lowe R, Mishkin D, Moore T, Oviedo J, Pedrosa M, Schimmel E, Schroy P, Singh S, Tseng C, Fallon M, Arguedas M, Garcia-Gallont R, Kochar R, McGuire B, Mönkemüller K, Neumann H, Sheikh A, Varadarajulu S, Berliner N, Lacy J, Rinder C, Rinder H, Rose M, Seropian S, Tormey C, Torres R, Wang E, Griggs J, Burtness B, Khorana A, Lantz P, Todd R, Smith R, Brooks D, Gopalakrishnan G, Hamdy O, Warren M, Ziegler T, Braunstein G, Barnett P, Herman-Bonert V, Friedman T, Charney P, Carney P, Ehrenthal D, Kottenhahn R, Smith J, Milam D, Starkman J, Stewart A, Greenspan S, Hodak S, Horwitz M, LeBeau S, Roodman G, Moreland L, Agarwal S, Ascherman D, Domsic R, Elliott J, Kao A, Koumpouras F, Kwoh C, Lienesch D, McKinnon-Maksimowicz K, Medsger T, Mohan N, Wing E, Armitage K, Beckwith C, Bobak D, Fairley J, Fulton S, Hileman C, Lange C, Lederman M, Lemonovich T, Lisagaris M, Ray A, Rodriguez B, Salata R, Watkins R, Bradsher R, Griggs R, Berg M, Ciafaloni E, Counihan T, Cheshire W, de los Reyes E, Griggs J, Jackson C, Kerber K, Liu L, Ling G, Lyness J, Lynn D, Marshall F, McCarthy A, Murphy S, Nath A, Roach E, Rogers L, Simon R, Cohen H, Heflin M, Quill T, Holloway R, Hillis L, Lange R. Lead Authors and Contributors 2010, ix-xix. DOI: 10.1016/b978-1-4160-6109-0.00138-6.
- Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor. Blood 2009, 114: 4233-4233. DOI: 10.1182/blood.v114.22.4233.4233.
- Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia American Journal Of Hematology 2009, 84: 599-600. PMID: 19650144, DOI: 10.1002/ajh.21478.
- Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.
- Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper D, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL) Blood 2008, 112: 3750-3750. DOI: 10.1182/blood.v112.11.3750.3750.
- Maggiore R, Cooper D, Foss F, Shlomchik W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: 2216-2216. DOI: 10.1182/blood.v112.11.2216.2216.
- Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience Blood 2008, 112: 4392-4392. DOI: 10.1182/blood.v112.11.4392.4392.
- Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood 2008, 112: 4396-4396. DOI: 10.1182/blood.v112.11.4396.4396.
- Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.
- Wu Y, Proytcheva M, Medoff E, Seropian S, Snyder E, Krause D, Cooper D. Successful Engraftment of Autologous Peripheral Blood Progenitor Cells Derived from Multiple Collections in Poor Mobilizers by Hyperstimulation with G-CSF. Blood 2005, 106: 5508-5508. DOI: 10.1182/blood.v106.11.5508.5508.
- Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: Expanding the sclerodermoid spectrum Journal Of The American Academy Of Dermatology 2005, 53: 591-601. PMID: 16198778, DOI: 10.1016/j.jaad.2005.06.015.
- Noronha V, Lekakis L, Ke J, Cooper D, Seropian S. Management of recurrent non-Hodgkin’s lymphoma (NHL) following allogeneic stem cell transplant (ALSCT) Journal Of Clinical Oncology 2005, 23: 6667-6667. DOI: 10.1200/jco.2005.23.16_suppl.6667.
- Baehring J, Cooper D, Seropian S, Bannykh S. Images in Neuro-Oncology Journal Of Neuro-Oncology 2004, 67: 189-189. PMID: 15072466, DOI: 10.1023/b:neon.0000021952.37526.49.
- New Approaches to allografting in non-Hodgkin's lymphoma.Seropian S, Cooper DL. New Approaches to allografting in non-Hodgkin's lymphoma. Progress in Oncology, 2004 Jones and Bartlett.
- Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.
- Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma Bone Marrow Transplantation 2003, 32: 763-769. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.
- Shinoura S, Jain D, Cooper D, Seropian S, Robert M. Chronic liver graft-versus-host disease presenting as acute hepatitis The American Journal Of Gastroenterology 2003, 98: s102-s102. DOI: 10.1111/j.1572-0241.2003.08036.x.
- Debelak J, Shlomchik M, Snyder E, Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs Transfusion 2000, 40: 1475-1481. PMID: 11134567, DOI: 10.1046/j.1537-2995.2000.40121475.x.
- Strasser S, Shulman H, Flowers M, Reddy R, Margolis D, Prumbaum M, Seropian S, McDonald G. Chronic graft‐versus‐host disease of the liver: Presentation as an acute hepatitis Hepatology 2000, 32: 1265-1271. PMID: 11093733, DOI: 10.1053/jhep.2000.20067.
- Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516, DOI: 10.1182/blood.v96.8.2814.h8002814_2814_2821.
- Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus–specific T lymphocytes following allogeneic stem cell transplantation Blood 2000, 96: 2814-2821. DOI: 10.1182/blood.v96.8.2814.
- Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.
- Hodgkin's DiseaseSeropian S, Cooper DL. Hodgkin's Diseases in Annual of Lymphoid Malignancies. Cavelli F, Longo D eds. 2000
- Autologous Stem Cell TransplantationCooper DL, Seropian S, Autologous Stem Cell Transplantation, in Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg S eds. 6th edition, 2000.
- McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.
- Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
- Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant Bone Marrow Transplantation 1998, 22: 507-509. PMID: 9733277, DOI: 10.1038/sj.bmt.1701354.
- Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.
- McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. PMID: 9815289.
Patient Care Organizations
Locations
Yale Medical Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th Floor Multispecialty Care Center
New Haven, CT 06511
- Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511
Biography
Stuart Seropian, MD, is a medical oncologist who specializes in treating patients with blood cancers, including acute and chronic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. Dr. Seropian also sees patients with non-cancerous bone marrow disorders, including aplastic anemia. He is director of the adult Stem Cell Transplant program and co-director of the CAR T-cell Therapy Program for adults.
In medical school, Dr. Seropian enjoyed studying the biology of cancer and wanted to provide long-term patient care, which led to his pursuing medical oncology. “I have patients who see me as their primary care physician—as the doctor most responsible for their long-term care,” Dr. Seropian says. “Patients will say they’ve experienced a physician who had one foot out the door before all questions were answered. But the relationship with the patient is vital for cancer treatment.”
During his career, Dr. Seropian has witnessed treatment options for patients with blood cancers improve by leaps and bounds, from chemotherapy to the personalized CAR T-cell and stem cell transplantation therapies.
“The general view among the public is that cancer is terminal,” Dr. Seropian says. “People are always surprised to hear that cure rates [for certain cancers] range from 30 to 65 percent.”
He points out that a transplant physician is one of many providers of care in a large cast, which includes other physician subspecialists, nurse practitioners, nurses, coordinators, laboratory physicians and technicians. “Patients who come here are cared for by a family of people,” he says.
Dr. Seropian is an associate professor of medicine (hematology) at Yale School of Medicine.
Titles
- Professor of Internal Medicine (Hematology)
- Acting Director, Stem Cell Transplantation
- Chairman, Car-T Cell Joint Steering Committee
- Director, Unrelated Donor Transplant Program, Stem Cell Transplantation
- Co-Director, Immune Effector Cell Therapy
- Co-Director, Adult CAR T-Cell Therapy Program
Education & Training
- ResidentYale-New Haven Hospital (1994)
- InternYale-New Haven Hospital (1992)
- MDGeorge Washington University (1991)
- BSTufts University (1984)
Additional Information
Honors & Recognitions
- Yale Cancer Center Award for Clinical Excellence: Yale Cancer Center (2016)
- David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology: Yale Cancer Center (2014)
- Alpha Omega Alpha Medical Honor Society: AOA (1991)
- MD with Distinction, George Washington University School of Medicine: George Washington University School of Medicine (1991)
- Horowitz Award, NBME Part I: George Washington University School of Medicine (1989)
Board Certifications
- AB of Internal Medicine, Medical Oncology (1997, recertified: 2018)
Professional Service
- Hodgkin’s Lymphoma Guidelines Panel, National Comprehensive Cancer Center Network (2016 - Present): Committee Member
- EMR User Group, Center for International Blood and Marrow Transplantation Research (CIBMTR) (2014 - Present): Member
- Bone Marrow Transplantation (2014 - Present): Ad Hoc Reviewer of journal submissions
- Transfusion (2014 - Present): Reviewer
- Search Committee, Chair of Pulmonary Section, Department of Medicine (2008 - 2010): Member
- Education Review Committee (2007 - 2008): Member
- Internship Selection Committee (2006 - 2007): Member
- The Bone Marrow Foundation (2001 - Present): Regular participant in public access patient/family online advice query activities.
- Protocol Review Committee (1999 - 2017): review all clinical research protocols submitted for scientific review in the Cancer Center prior to IRB submission
Publications
- Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Mirza A, Hamouche R, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 513 Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s383-s384. DOI: 10.1016/s2666-6367(23)00581-x.
- Hamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience Transplantation And Cellular Therapy 2023, 29: s387-s388. DOI: 10.1016/s2666-6367(23)00585-7.
- Di M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen Transplantation And Cellular Therapy 2023, 29: s392. DOI: 10.1016/s2666-6367(23)00591-2.
- Di M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
- Browning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
- Liu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
- Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.
- Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
- Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Chen G, Al-Kadhimi Z, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. 40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies Transplantation And Cellular Therapy 2022, 28: s35-s36. DOI: 10.1016/s2666-6367(22)00201-9.
- Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease Journal Of Clinical Oncology 2022, 40: 1174-1185. PMID: 35007144, PMCID: PMC8987226, DOI: 10.1200/jco.21.01755.
- Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Al-Kadhimi Z, Chen G, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies Blood 2021, 138: 1791-1791. DOI: 10.1182/blood-2021-148497.
- Gowda L, Seropian S. Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul? JAMA Oncology 2021, 7: 1611-1613. PMID: 34499090, DOI: 10.1001/jamaoncol.2021.3674.
- Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy Annals Of Hematology 2021, 101: 1145-1147. PMID: 34686913, DOI: 10.1007/s00277-021-04702-w.
- Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.
- Gisriel S, Hung K, Braddock D, Seropian S, Foss F, Robert M, Xu M. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis Human Pathology Case Reports 2021, 24: 200507. DOI: 10.1016/j.ehpc.2021.200507.
- Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.
- Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT) Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.
- Nath R, Gyurkocza B, Choe H, Seropian S, Stiff P, Agura E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 59 Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Transplantation And Cellular Therapy 2021, 27: s56. DOI: 10.1016/s2666-6367(21)00085-3.
- Gerstein R, Schiffer M, Perreault S, Gowda L, Foss F, Isufi I, Seropian S. 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Transplantation And Cellular Therapy 2021, 27: s466-s467. DOI: 10.1016/s2666-6367(21)00606-0.
- Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Agura E, Abhyankar S, Litzow M, Tomlinson B, Abboud C, Chen G, Hari P, Orozco J, Sabloff M, Al-Kadhimi Z, Van Besien K, Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. 60 Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered Transplantation And Cellular Therapy 2021, 27: s57-s58. DOI: 10.1016/s2666-6367(21)00086-5.
- Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Journal Of Health-System Pharmacy 2021, 78: zxab072. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Sharma A, Bhatt N, St. Martin A, Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda L, Perales M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study Transplantation And Cellular Therapy 2021, 27: s4-s5. PMCID: PMC7847402, DOI: 10.1016/s2666-6367(21)00031-2.
- Gupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection Transfusion And Apheresis Science 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.
- Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.
- Perreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.
- Browning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. DOI: 10.1182/blood-2020-136478.
- Gupta G, Perreault S, Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection Blood 2020, 136: 41-41. DOI: 10.1182/blood-2020-140171.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-134624.
- Gyurkocza B, Nath R, Choe H, Seropian S, Stiff P, Abhyankar S, Agura E, Litzow M, Tomlinson B, Chen G, Hari P, Orozco J, Al-Kadhimi Z, Abboud C, Van Besien K, Sabloff M, Magalhaes-Silverman M, Foran J, Schuster M, Kebriaei P, Levy M, Lazarus H, Giralt S, Liang Q, Berger M, Reddy V, Pagel J. Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered Blood 2020, 136: 42-44. DOI: 10.1182/blood-2020-134948.
- Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial Clinical Lymphoma Myeloma & Leukemia 2020, 20: s182. DOI: 10.1016/s2152-2650(20)30716-3.
- Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 755-781. PMID: 32502987, DOI: 10.6004/jnccn.2020.0026.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience* Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Transplantation And Cellular Therapy 2020, 26: s32-s33. DOI: 10.1016/j.bbmt.2019.12.575.
- Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.
- Bewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Shallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center Blood 2019, 134: 5569-5569. DOI: 10.1182/blood-2019-130134.
- Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood 2019, 134: 4055-4055. DOI: 10.1182/blood-2019-128888.
- Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2019, 134: 5642-5642. DOI: 10.1182/blood-2019-122776.
- Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT) Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.
- Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
- Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
- Shallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
- Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN) Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Agura E, Gyurkocza B, Nath R, Litzow M, Tomlinson B, Abhyankar S, Seropian S, Stiff P, Choe H, Kebriaei P, Foran J, Chen G, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial Blood 2018, 132: 1017-1017. DOI: 10.1182/blood-2018-99-111914.
- Ahmad H, Perreault S, McManus D, Foss F, Isufi I, Seropian S, Topal J. 2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum Infectious Diseases 2018, 5: s746-s746. PMCID: PMC6255683, DOI: 10.1093/ofid/ofy210.2140.
- Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Shimer S, Canavan M, Capasso R, Gore S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute leukemia: Patient-physician differences. Journal Of Clinical Oncology 2018, 36: e22124-e22124. DOI: 10.1200/jco.2018.36.15_suppl.e22124.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 245-254. PMID: 29523663, DOI: 10.6004/jnccn.2018.0013.
- Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies Transplantation And Cellular Therapy 2018, 24: s307. DOI: 10.1016/j.bbmt.2017.12.353.
- Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Musick W, Vuong N, Aitken S, Liao S, McManus D, Cox J, Perez K, Tichy E, Topal J, Seropian S, Danziger L, Garey K. Multi-center Observational Characterization of Cytomegalovirus Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) Recipients Open Forum Infectious Diseases 2017, 4: s715-s715. DOI: 10.1093/ofid/ofx163.1922.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168 Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
- Anderson A, McManus D, Perreault S, Lo YC, Seropian S, Topal JE. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient Medical Mycology Case Reports 2017, 17: 11-13. PMID: 28580237, PMCID: PMC5447657, DOI: 10.1016/j.mmcr.2017.05.004.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 608-638. PMID: 28476741, DOI: 10.6004/jnccn.2017.0064.
- Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.
- Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT) Transplantation And Cellular Therapy 2017, 23: s395-s396. DOI: 10.1016/j.bbmt.2016.12.616.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial Blood 2016, 128: 2139-2139. DOI: 10.1182/blood.v128.22.2139.2139.
- Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis Circulation Cardiovascular Imaging 2016, 9: e004770. PMID: 27682238, DOI: 10.1161/circimaging.116.004770.
- Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.
- Perreault S, Pratt K, Baker J, Medoff E, Foss F, Isufi I, Seropian S, Cooper D. Carmustine Infusion Reactions Are Common and Not Reduced By Lengthening the Time of Administration Transplantation And Cellular Therapy 2016, 22: s130-s131. DOI: 10.1016/j.bbmt.2015.11.462.
- Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.
- Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders Blood 2015, 126: 3058-3058. DOI: 10.1182/blood.v126.23.3058.3058.
- Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- Das R, Sehgal K, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar K, Dhodapkar M. Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets 2015, 1354-1354. DOI: 10.1158/1538-7445.am2015-1354.
- Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 554-86. PMID: 25964641, PMCID: PMC4898052, DOI: 10.6004/jnccn.2015.0075.
- Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.
- Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant Journal For ImmunoTherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.
- Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T‐cell lymphoma British Journal Of Haematology 2014, 167: 141-144. PMID: 24888971, DOI: 10.1111/bjh.12944.
- Disorders of LymphocytesLacy J, Seropian, S, Disorders of Lymphocytes, Andreoli: in Cecil Essentials of Medicine, 9th ed. 2014
- Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience Blood 2013, 122: 5092-5092. DOI: 10.1182/blood.v122.21.5092.5092.
- Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients Blood 2013, 122: 4356-4356. DOI: 10.1182/blood.v122.21.4356.4356.
- Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation Palliative & Supportive Care 2013, 12: 53-61. PMID: 24169207, DOI: 10.1017/s1478951513000552.
- Bleakley M, Heimfeld S, Jones L, Chaney C, Turtle C, Gooley T, Seropian S, Nishihori T, Riddell S, Shlomchik W. Depletion of Naïve T Cells From Peripheral Blood Stem Cell Grafts for GVHD Prevention Transplantation And Cellular Therapy 2013, 19: s318. DOI: 10.1016/j.bbmt.2012.11.477.
- LeukemiaRoberts K, Seropian S, Marks, P, Leukemia, Perez and Brady’s In Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
- Total-Body and HemiBody IrradiationRoberts K, Chen, Z, Seropian S. Total-Body and HemiBody Irradiation, Perez and Brady’s Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
- LymphomaIsufi I, Seropian S, Lymphoma, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
- Plasma Cell DisordersSeropian S, Isufi I, Plasma Cell Disorders, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
- Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.
- Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.
- Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor Journal Of Clinical Apheresis 2012, 27: 235-241. PMID: 22566214, DOI: 10.1002/jca.21232.
- Isufi I, Yao X, Seropian S, Cooper D, Shlomchik W, Deng Y, Barbarotta L, Foss F. Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies Transplantation And Cellular Therapy 2012, 18: s339. DOI: 10.1016/j.bbmt.2011.12.356.
- Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective Evaluation of Acute Graft-Versus-Host Disease Digestive Diseases And Sciences 2011, 57: 720-725. PMID: 22011927, DOI: 10.1007/s10620-011-1938-x.
- King BA, Seropian S, Fox LP. Disseminated fusarium infection with muscle involvement Journal Of The American Academy Of Dermatology 2011, 65: 235-237. PMID: 21679835, DOI: 10.1016/j.jaad.2009.12.034.
- Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.
- Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss F, Cooper D, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood 2010, 116: 1309-1309. DOI: 10.1182/blood.v116.21.1309.1309.
- Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816-2816. DOI: 10.1182/blood.v116.21.2816.2816.
- Lansigan F, Komarovskaya M, Seropian S, Cooper D, Foss F. A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients. Journal Of Clinical Oncology 2010, 28: tps300-tps300. DOI: 10.1200/jco.2010.28.15_suppl.tps300.
- Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis Nature Reviews Clinical Oncology 2010, 7: 415-420. PMID: 20404855, DOI: 10.1038/nrclinonc.2010.40.
- Benjamin I, Tariq S, Beland S, Benjamin I, Bull D, Hamdan M, Li D, Litwin S, Michaels A, Morshedzadeh J, Stehlik J, Whitehead K, Victor R, Vongpatanasin W, Rounds S, Aliotta J, Casserly B, Jankowich M, McCool F, Eagle K, Lau W, Harris R, Andreoli T, Basford A, Cavanaugh K, Dwyer J, Golper T, Krause M, Ikizler T, Lewis J, Luther J, Pirkle J, Portilla D, Safirstein R, Schulman G, Shah S, Zent R, Wolfe M, Blanton W, Bliss C, Farraye F, Huang C, Jacobson B, Lichtenstein D, Lowe R, Mishkin D, Moore T, Oviedo J, Pedrosa M, Schimmel E, Schroy P, Singh S, Tseng C, Fallon M, Arguedas M, Garcia-Gallont R, Kochar R, McGuire B, Mönkemüller K, Neumann H, Sheikh A, Varadarajulu S, Berliner N, Lacy J, Rinder C, Rinder H, Rose M, Seropian S, Tormey C, Torres R, Wang E, Griggs J, Burtness B, Khorana A, Lantz P, Todd R, Smith R, Brooks D, Gopalakrishnan G, Hamdy O, Warren M, Ziegler T, Braunstein G, Barnett P, Herman-Bonert V, Friedman T, Charney P, Carney P, Ehrenthal D, Kottenhahn R, Smith J, Milam D, Starkman J, Stewart A, Greenspan S, Hodak S, Horwitz M, LeBeau S, Roodman G, Moreland L, Agarwal S, Ascherman D, Domsic R, Elliott J, Kao A, Koumpouras F, Kwoh C, Lienesch D, McKinnon-Maksimowicz K, Medsger T, Mohan N, Wing E, Armitage K, Beckwith C, Bobak D, Fairley J, Fulton S, Hileman C, Lange C, Lederman M, Lemonovich T, Lisagaris M, Ray A, Rodriguez B, Salata R, Watkins R, Bradsher R, Griggs R, Berg M, Ciafaloni E, Counihan T, Cheshire W, de los Reyes E, Griggs J, Jackson C, Kerber K, Liu L, Ling G, Lyness J, Lynn D, Marshall F, McCarthy A, Murphy S, Nath A, Roach E, Rogers L, Simon R, Cohen H, Heflin M, Quill T, Holloway R, Hillis L, Lange R. Lead Authors and Contributors 2010, ix-xix. DOI: 10.1016/b978-1-4160-6109-0.00138-6.
- Cooper D, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder E, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor. Blood 2009, 114: 4233-4233. DOI: 10.1182/blood.v114.22.4233.4233.
- Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia American Journal Of Hematology 2009, 84: 599-600. PMID: 19650144, DOI: 10.1002/ajh.21478.
- Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.
- Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper D, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL) Blood 2008, 112: 3750-3750. DOI: 10.1182/blood.v112.11.3750.3750.
- Maggiore R, Cooper D, Foss F, Shlomchik W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: 2216-2216. DOI: 10.1182/blood.v112.11.2216.2216.
- Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience Blood 2008, 112: 4392-4392. DOI: 10.1182/blood.v112.11.4392.4392.
- Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood 2008, 112: 4396-4396. DOI: 10.1182/blood.v112.11.4396.4396.
- Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.
- Wu Y, Proytcheva M, Medoff E, Seropian S, Snyder E, Krause D, Cooper D. Successful Engraftment of Autologous Peripheral Blood Progenitor Cells Derived from Multiple Collections in Poor Mobilizers by Hyperstimulation with G-CSF. Blood 2005, 106: 5508-5508. DOI: 10.1182/blood.v106.11.5508.5508.
- Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: Expanding the sclerodermoid spectrum Journal Of The American Academy Of Dermatology 2005, 53: 591-601. PMID: 16198778, DOI: 10.1016/j.jaad.2005.06.015.
- Noronha V, Lekakis L, Ke J, Cooper D, Seropian S. Management of recurrent non-Hodgkin’s lymphoma (NHL) following allogeneic stem cell transplant (ALSCT) Journal Of Clinical Oncology 2005, 23: 6667-6667. DOI: 10.1200/jco.2005.23.16_suppl.6667.
- Baehring J, Cooper D, Seropian S, Bannykh S. Images in Neuro-Oncology Journal Of Neuro-Oncology 2004, 67: 189-189. PMID: 15072466, DOI: 10.1023/b:neon.0000021952.37526.49.
- New Approaches to allografting in non-Hodgkin's lymphoma.Seropian S, Cooper DL. New Approaches to allografting in non-Hodgkin's lymphoma. Progress in Oncology, 2004 Jones and Bartlett.
- Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.
- Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma Bone Marrow Transplantation 2003, 32: 763-769. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.
- Shinoura S, Jain D, Cooper D, Seropian S, Robert M. Chronic liver graft-versus-host disease presenting as acute hepatitis The American Journal Of Gastroenterology 2003, 98: s102-s102. DOI: 10.1111/j.1572-0241.2003.08036.x.
- Debelak J, Shlomchik M, Snyder E, Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs Transfusion 2000, 40: 1475-1481. PMID: 11134567, DOI: 10.1046/j.1537-2995.2000.40121475.x.
- Strasser S, Shulman H, Flowers M, Reddy R, Margolis D, Prumbaum M, Seropian S, McDonald G. Chronic graft‐versus‐host disease of the liver: Presentation as an acute hepatitis Hepatology 2000, 32: 1265-1271. PMID: 11093733, DOI: 10.1053/jhep.2000.20067.
- Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516, DOI: 10.1182/blood.v96.8.2814.h8002814_2814_2821.
- Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus–specific T lymphocytes following allogeneic stem cell transplantation Blood 2000, 96: 2814-2821. DOI: 10.1182/blood.v96.8.2814.
- Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.
- Hodgkin's DiseaseSeropian S, Cooper DL. Hodgkin's Diseases in Annual of Lymphoid Malignancies. Cavelli F, Longo D eds. 2000
- Autologous Stem Cell TransplantationCooper DL, Seropian S, Autologous Stem Cell Transplantation, in Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg S eds. 6th edition, 2000.
- McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.
- Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
- Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant Bone Marrow Transplantation 1998, 22: 507-509. PMID: 9733277, DOI: 10.1038/sj.bmt.1701354.
- Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.
- McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. PMID: 9815289.
Patient Care Organizations
Locations
Yale Medical Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th Floor Multispecialty Care Center
New Haven, CT 06511
- Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511
Yale Medical Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th Floor Multispecialty Care Center
New Haven, CT 06511
- Yale Medical OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 7th Floor Multispecialty Care CenterNew Haven, CT 06511